Nanoparticle modification of human adipose-derived mesenchymal stem cells for treating brain cancer and other neurological diseases

A method for treating a brain tumor in a patient in need thereof, the method comprising:

• administering to the patient, nanoparticle-modified, adipose-derived mesenchymal stem cells (AMSCs) comprising AMSCs containing a nanoparticle formulation comprising biodegradable polymers self-assembled with nucleic acid molecules,
• wherein the biodegradable polymer is selected from the group consisting of 2-(3-aminopropylamino)ethanol end-modified poly(1, 4-butanediol diacrylate-co-4-amino-1-butanol), (1-(3-aminopropyl)-4-methylpiperazine end-modified poly(1,4-butanediol diacrylate-co-4-amino-1-butanol), 2-(3-aminopropylamino)ethanol end-modified poly(1,4-butanediol diacrylateco-5-amino-1-pentanol), (1-(3-aminopropyl)-4-methylpiperazine end-modified poly(1,4-butanediol diacrylate-co-5-amino-1-pentanol), 2-(3-aminopropylamino)ethanol end-modified poly(1,5 pentanediol diacrylate-co-3-amino-1-propanol), and (1-(3-aminopropyl)-4-methylpiperazine-end-modified poly(1,5 pentanediol diacrylate-co-3-amino-1-propanol),
• wherein the nanoparticle formulation has a polymer to nucleic acid weight ratio of 25 to 75 weight polymer:weight nucleic acid,
• wherein the nucleic acid molecules encode one or more anti-cancer agents selected from the group consisting of bone morphogenic protein 4 (BMP4), TNF related apoptosis-inducing ligand (TRAIL), HSV-thymidine kinase, an oncolytic adenovirus, interleukin-2 (IL-2), interleukin-12 (IL-12), interleukin-18 (IL-18), interleukin-23 (IL-23), Interferon-α, and Interferon-β.